Table 2.

Number of subjects experiencing first MACE and mean observation time in the semaglutide trials

	Semaglutide				Comparator
	n	N	(%)	Observation time, total (mean), patient-years	n	N	(%)	Observation time, total (mean), patient-years
CVOTs	167	3,239	5.2	5,464 (1.69)	217	3,241	6.7	5,434 (1.68)
Glycemic efficacy trials	55	7,269	0.8	7,636 (1.05)	34	3,896	0.9	4,000 (1.03)
Overall	222	10,508	2.1	13,099 (1.25)	251	7,137	3.5	9,434 (1.32)

Observation time is curtailed at a maximum of 109 weeks to align with the analysis timeframe

% proportion of subjects, CVOT cardiovascular outcomes trial, MACE major adverse cardiovascular events, n number of subjects with events, N number of subjects in full analysis set